Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Inclusion Criteria: * Male or female patients aged 18-60. * Treatment-naïve, HL patients with Ann Arbor stage I or II A non-bulky disease stratified according to modified EORTC Criteria (refer to Appendix A); * Patients must have histologically confirmed classical HL according to the current World Health Organization Classification (nodular sclerosis, mixed cellularity, lymphocytes rich, lymphocytes depleted, or classical HL NOS \[not otherwise specified\]; * ECOG performance status 0-2 * Hemoglobin must be \> 8 gr./dL * Absolute neutrophil count ≥ 1,000/μL * Platelet count ≥ 100,000/μL * Voluntary written consent to take part to the study * Serum Creatinine \< 2.0 mg/dL and/or Creatinine clearance or calculated Creatinine clearance \> 40 mL/minute * Total bilirubin must be \< 2.0 x the upper limit of normal (ULN) unless known Gilbert syndrome * ALT or AST must be \< 3 x the upper limit of normal. * Female patients: if postmenopausal for at least 1 year before enrolment or, if fertile - agreeing to practice 2 effective methods of contraception or agreeing to practice true abstinence. * Male patients should agree to practice barrier contraception or to practice abstinence Exclusion Criteria: * Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma; * Bulky disease (Lugano 2014 definition: single or conglomerated nodal mass with the largest diameter measuring 10 or more centimeters); * B symptoms; * Extra nodal site involved by disease; * Female patients who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug; * Uncompensated diabetes mellitus requiring insulin therapy; * Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol; * Known human immunodeficiency virus (HIV) infection with a positive search for HIV antigens by immunoblot and/or circulating copies of HIV-RNA; * Active hepatitis B with circulating copies of HBV-DNA, or active hepatitis C infection with circulating copies of HCV-RNA; * Severely impaired, lung and renal function; * Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; * Active autoimmune disorder in treatment with immunosuppressive drugs * A left-ventricular ejection fraction \< 50%; * Myocardial infarction within 2 years of study entry. * Pregnancy or lactation.